Age : 18-65
Patients with major depressive disorder according to DSM-IV criteria that have lasted >8 weeks
MADRS total score of 18 or higher
Patients who responded inadequately (a score of >18 on the MADRS) to first-line antidepressant treatment of 4 week duration
Current use of standard antidepressant treatment in monotherapy or combination of 2 antidepressants : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)

NCT01696617_inc_T1
Person
Age
NCT01696617_inc_T2
Value
18-65
NCT01696617_inc_T3
Condition
major depressive disorder
NCT01696617_inc_T4
Measurement
DSM-IV criteria
NCT01696617_inc_T5
Temporal
lasted >8 weeks
NCT01696617_inc_T6
Measurement
MADRS
NCT01696617_inc_T7
Value
score of 18 or higher
NCT01696617_inc_T8
Measurement
MADRS
NCT01696617_inc_T9
Value
score of >18
NCT01696617_inc_T10
Qualifier
first-line
NCT01696617_inc_T11
Drug
antidepressant
NCT01696617_inc_T12
Temporal
of 4 week
NCT01696617_inc_T13
Observation
responded inadequately
NCT01696617_inc_T14
Qualifier
standard
NCT01696617_inc_T15
Drug
antidepressant
NCT01696617_inc_T16
Qualifier
monotherapy
NCT01696617_inc_T17
Multiplier
2
NCT01696617_inc_T18
Drug
antidepressants
NCT01696617_inc_T19
Drug
escitalopram
NCT01696617_inc_T20
Drug
fluoxetine
NCT01696617_inc_T21
Drug
paroxetine CR
NCT01696617_inc_T22
Drug
sertraline
NCT01696617_inc_T23
Drug
mirtazapine
NCT01696617_inc_T24
Drug
duloxetine
NCT01696617_inc_T25
Multiplier
10 - 20mg/d
NCT01696617_inc_T26
Multiplier
20 - 40mg/d
NCT01696617_inc_T27
Multiplier
25 - 50mg/d
NCT01696617_inc_T28
Multiplier
100 - 150mg/d
NCT01696617_inc_T29
Multiplier
15 - 45mg/d
NCT01696617_inc_T30
Multiplier
30 - 60mg/d
NCT01696617_inc_T31
Drug
venlafaxine ER
NCT01696617_inc_T32
Multiplier
150-225mg/d
NCT01696617_inc_T33
Scope
escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)
NCT01696617_inc_T34
Scope
standard antidepressant treatment in monotherapy or combination of 2 antidepressants